Last 48 quarters of trend data · Healthcare · Rare Disease Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 55.34 | 28.52 | 60.38 | — | 43.50 | 129.86 | 63.28 | 167.97 | 48.45 | 28.22 | 25.38 | 25.19 | 29.00 | 24.33 | 22.25 | 38.68 | 36.27 | 21.37 | 24.77 | 28.15 | 19.04 |
| — | -78.0% | -4.6% | — | -10.2% | +360.2% | +149.3% | +566.8% | +67.1% | +16.0% | +14.1% | -34.9% | -20.0% | +13.8% | -10.2% | +37.4% | +90.5% | +4.2% | -5.4% | -14.8% | -41.8% | |
| P/S Ratio | 8.11 | 10.42 | 10.05 | 6.38 | 5.16 | 11.95 | 11.37 | 21.76 | 8.20 | 7.21 | 5.52 | 4.71 | 6.65 | 6.12 | 5.18 | 5.92 | 5.73 | 7.35 | 6.64 | 6.91 | 6.13 |
| — | -12.8% | -11.6% | -70.7% | -37.1% | +65.8% | +106.1% | +361.6% | +23.4% | +17.7% | +6.5% | -20.3% | +16.0% | -16.7% | -22.0% | -14.4% | -6.5% | +14.7% | -12.8% | -28.8% | -36.9% | |
| P/B Ratio | 13.48 | 17.03 | 14.58 | 6.60 | 6.44 | 15.71 | 13.91 | 20.03 | 8.78 | 8.24 | 6.06 | 5.05 | 7.11 | 6.56 | 5.78 | 4.72 | 4.71 | 6.32 | 6.20 | 6.35 | 6.45 |
| — | +8.4% | +4.9% | -67.1% | -26.7% | +90.7% | +129.5% | +296.3% | +23.6% | +25.7% | +4.8% | +7.1% | +51.0% | +3.8% | -6.8% | -25.7% | -27.0% | +38.6% | +16.4% | +5.2% | +1.3% | |
| P/FCF | 40.14 | 24.96 | 82.97 | — | 27.16 | 45.55 | 50.38 | 681.02 | 25.22 | 18.23 | 22.17 | 29.14 | 152.95 | 14.31 | 14.45 | 24.08 | 17.71 | 22.45 | 38.07 | 18.38 | 12.28 |
| — | -45.2% | +64.7% | — | +7.7% | +149.9% | +127.3% | +2237.3% | -83.5% | +27.3% | +53.4% | +21.0% | +763.8% | -36.2% | -62.0% | +31.0% | +44.2% | +77.0% | +141.6% | -39.7% | -49.0% | |
| EV / EBITDA | 67.59 | 30.47 | 60.43 | — | 204.09 | 229.24 | 80.57 | 876.92 | 56.84 | 27.24 | 24.35 | 22.11 | 26.88 | 23.16 | 18.96 | 36.33 | 24.71 | 22.50 | 21.11 | 22.96 | 15.66 |
| — | -86.7% | -25.0% | — | +259.1% | +741.4% | +230.9% | +3866.9% | +111.5% | +17.6% | +28.4% | -39.2% | +8.8% | +2.9% | -10.2% | +58.3% | +57.7% | +40.6% | +2.5% | -38.3% | -40.3% | |
| EV / EBIT | 171.83 | 29.31 | 55.47 | — | 102.34 | 160.86 | 69.00 | 353.58 | 45.75 | 24.24 | 20.98 | 18.71 | 27.36 | 23.38 | 19.15 | 37.04 | 25.53 | 23.03 | 21.56 | 23.64 | 16.00 |
| — | -81.8% | -19.6% | — | +123.7% | +563.7% | +228.8% | +1789.6% | +67.2% | +3.7% | +9.6% | -49.5% | +7.2% | +1.5% | -11.2% | +56.7% | +59.5% | +40.9% | +2.3% | -38.8% | -40.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.3% | 98.6% | 98.4% | 98.3% | 98.7% | 97.8% | 98.2% | 98.5% | 98.4% | 98.4% | 98.5% | 98.3% | 98.6% | 98.7% | 98.7% | 98.7% | 98.6% | 98.7% | 98.7% | 98.7% | 98.6% |
| — | +0.9% | +0.2% | -0.2% | +0.4% | -0.7% | -0.2% | +0.2% | -0.2% | -0.2% | -0.2% | -0.4% | +0.1% | -0.0% | -0.1% | +0.0% | -0.1% | +0.0% | +0.2% | +0.3% | +0.1% | |
| Operating Margin | 5.9% | 33.7% | 16.1% | -30.1% | 2.2% | 4.9% | 13.7% | 2.2% | 13.9% | 25.5% | 21.7% | 20.1% | 23.4% | 25.2% | 25.1% | 14.1% | 21.8% | 31.4% | 30.4% | 28.6% | 37.1% |
| — | +584.7% | +17.5% | -1484.3% | -84.0% | -80.7% | -36.9% | -89.2% | -40.6% | +1.2% | -13.5% | +42.9% | +7.1% | -19.6% | -17.3% | -50.8% | -41.2% | -16.7% | -12.8% | +15.6% | +4.3% | |
| Net Margin | 13.1% | 37.2% | 16.5% | -18.9% | 12.0% | 9.5% | 18.1% | 13.1% | 16.7% | 25.6% | 21.7% | 18.9% | 23.2% | 25.4% | 23.4% | 15.0% | 16.1% | 34.0% | 26.5% | 24.3% | 32.4% |
| — | +293.1% | -9.0% | -244.8% | -28.1% | -63.0% | -16.6% | -30.9% | -27.9% | +0.8% | -7.4% | +25.8% | +43.8% | -25.4% | -11.8% | -38.2% | -50.3% | +7.3% | -8.4% | -17.6% | +7.0% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 15.0% | 16.5% | 6.3% | -4.9% | 3.8% | 3.1% | 5.3% | 3.0% | 4.6% | 7.6% | 6.2% | 5.3% | 6.5% | 7.1% | 5.8% | 3.1% | 3.4% | 7.6% | 6.4% | 5.8% | 7.0% |
| — | +430.8% | +17.7% | -261.0% | -17.7% | -59.0% | -14.1% | -42.7% | -28.8% | +6.4% | +7.2% | +71.0% | +90.2% | -6.0% | -10.2% | -47.1% | -51.4% | +31.8% | +25.6% | +28.2% | +36.4% | |
| ROA | 11.9% | 13.2% | 4.9% | -3.8% | 2.9% | 2.4% | 4.3% | 2.4% | 3.7% | 6.2% | 5.2% | 4.3% | 5.2% | 5.6% | 4.8% | 2.6% | 3.0% | 6.7% | 5.7% | 5.1% | 6.4% |
| — | +444.9% | +16.0% | -255.1% | -21.8% | -61.2% | -17.6% | -44.0% | -27.5% | +11.1% | +7.5% | +64.4% | +73.5% | -16.5% | -15.2% | -48.3% | -53.2% | +27.3% | +20.1% | +22.5% | +35.1% | |
| ROIC | 6.2% | 12.8% | 5.4% | -6.9% | 0.6% | 1.5% | 3.5% | 0.4% | 3.6% | 7.1% | 6.1% | 5.8% | 6.6% | 7.8% | 9.2% | 3.3% | 3.9% | 5.7% | 6.2% | 6.2% | 7.4% |
| — | +776.7% | +54.4% | -1669.8% | -81.9% | -79.6% | -42.7% | -92.3% | -46.1% | -8.7% | -33.8% | +72.1% | +68.1% | +35.8% | +48.7% | -46.1% | -46.9% | -7.5% | +15.4% | +91.6% | +47.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| — | +7.2% | +28.5% | +51.0% | -7.6% | -5.3% | +9.3% | +7096.4% | +3324.8% | +2082.8% | +1250.6% | -87.2% | -86.9% | -86.5% | -86.2% | -84.3% | +62.7% | +86.3% | +71.6% | +70.6% | -71.3% | |
| Debt / EBITDA | 0.13 | 0.08 | 0.22 | — | 1.23 | 0.59 | 0.24 | 1.76 | 0.27 | 0.14 | 0.16 | 0.00 | 0.00 | 0.01 | 0.01 | 0.04 | 0.05 | 0.05 | 0.07 | 0.10 | 0.01 |
| — | -86.9% | -8.2% | — | +355.8% | +312.2% | +53.9% | +68586.9% | +5658.1% | +1916.4% | +1491.4% | -93.2% | -90.5% | -86.3% | -85.9% | -62.8% | +250.2% | +84.7% | +47.9% | +0.7% | -82.9% | |
| Current Ratio | 2.92 | 3.00 | 2.86 | 2.86 | 2.92 | 3.14 | 3.06 | 3.07 | 3.35 | 3.70 | 5.57 | 5.18 | 4.39 | 3.54 | 4.65 | 6.77 | 6.89 | 8.52 | 8.54 | 6.78 | 5.60 |
| — | -4.3% | -6.7% | -6.8% | -12.7% | -15.1% | -45.0% | -40.8% | -23.7% | +4.5% | +19.8% | -23.5% | -36.3% | -58.5% | -45.6% | -0.2% | +22.9% | -5.1% | -5.7% | -32.8% | -44.4% | |
| Quick Ratio | 2.85 | 2.94 | 2.77 | 2.77 | 2.85 | 3.07 | 2.98 | 2.96 | 3.26 | 3.64 | 5.48 | 5.10 | 4.31 | 3.48 | 4.57 | 6.69 | 6.80 | 8.41 | 8.43 | 6.69 | 5.50 |
| — | -4.3% | -6.9% | -6.6% | -12.8% | -15.6% | -45.7% | -41.9% | -24.4% | +4.5% | +19.9% | -23.7% | -36.6% | -58.6% | -45.7% | -0.1% | +23.7% | -5.2% | -5.9% | -32.8% | -44.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CORT stock.
Corcept Therapeutics Incorporated's current P/E is 55.3x. The average P/E over the last 3 quarters is 44.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Corcept Therapeutics Incorporated's current operating margin is 5.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Corcept Therapeutics Incorporated's business trajectory between earnings reports.